Navigation Links
Phase 2a Findings Demonstrate that CSL112, A Novel Apolipoprotein A-I Infusion Therapy, Has a Favorable Safety Profile, is Well Tolerated and Increases Cholesterol Efflux Capacity in Stable Atherothrombotic Patients

dy of CSL112 support our continued enthusiasm for its development as a novel approach to address this important therapeutic void."

About CSL112
CSL112 is a novel formulation of apolipoprotein A-I (apoA-I), the active component of high-density lipoprotein (HDL). It is purified from human plasma and reconstituted to form HDL particles suitable for intravenous infusion. Studies have shown the infusion of CSL112 rapidly elevates markers of reverse cholesterol efflux, a process by which cholesterol is removed from arteries and transported to the liver for clearance. CSL112 may offer a novel option for rapidly stabilizing atherosclerotic lesions and is being studied for reduction in the risk of early atherothrombotic events in acute coronary syndrome (ACS) patients. 

About CSL
Headquartered in Melbourne, Australia, CSL Limited is a global biopharmaceutical company that develops, manufactures and markets biotherapies to prevent and treat rare and serious human diseases. CSL owns major facilities in Australia, Germany, Switzerland and the United States, and employs over 11,000 people in more than 25 countries. Visit for more information.


Sheila A. Burke
Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
C: 484-919-2618

Eliot Harrison
MCS Healthcare Public Relations
C: 908-884-5252

Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Commences Phase 2 Clinical Trial of XAF5 Gel to Reduce Submental Fat
2. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Surprise: Viruses Can Cause Disease during Latent Phase; New Evidence Supports Microcompetition Theory
4. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
5. Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
6. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
7. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
8. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
9. KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
10. Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma
11. Xencors XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Post Your Comments:
(Date:10/8/2015)... 2015  The ALS Association, in partnership with Prize4Life, ... to revolutionize communication technology solutions for people living with ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease ... the spinal cord. Eventually, people with ALS lose the ... leads to total paralysis and death within two to ...
(Date:10/8/2015)... 8, 2015  Today the Wyss Institute for Biologically ... its start-up company Opsonix Inc. The announcement ... Office of Technology Development (OTD) and Opsonix Inc. ... for clinical use. --> ... million people every year in the U.S. — more ...
(Date:10/8/2015)... ... , ... Talon Innovations, a provider of Precision Machined Products and ... is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in the ... Innovations was recognized as a nominee for this competitive award. , The “Best ...
(Date:10/8/2015)... , ... October 08, 2015 , ... ... the cystic fibrosis transmembrane conductance regulator (CFTR) gene and results in dysfunction of ... sticky mucus accumulates in the lungs. This mucus is very difficult to clear, ...
Breaking Biology Technology:
... BEIJING, July 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... of vaccines in China, announced today,that its Annual General Meeting ... 30, 2009. , At the July ... of the outstanding shares was not present. In accordance with ...
... , , , SEATTLE, July ... series A financing round. The infusion of capital assures the company of the ... of cellulosic materials (such as algae, plants and food waste) into a sustainable ... of the agreement, the lead investor has joined the board of Blue Marble ...
... ... System enables acute monitoring, signal detection and analysis to facilitate development ... treatment of a wide range of brain disorders including Epilepsy and ... as many as 256 channels, with the potential to be scalable ...
Cached Biology Technology:
(Date:9/28/2015)... 28, 2015 Synaptics Inc. (NASDAQ: SYNA ... announced that Lenovo has selected Synaptics , Natural ... its latest smartphone, the Vibe P1. The new ... the device and provide swift access to applications and ... Natural ID FS4202 sensor solution utilizes AES256-bit encryption of ...
(Date:9/10/2015)... -- This report provides detailed descriptions of the sensor ... sensor types that will dominate in the future. Many ... wearable technology hype curve in the last five years ... with all of them is the prominence of sensor ... functions. Sensors collect data about the physical and chemical ...
(Date:9/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that the ... Modern, will feature the Wocket® smart wallet for the ... Touch Of Modern is an online ... to its 7.2 million members. Customers are affluent, urban ...
Breaking Biology News(10 mins):
... Inc., announced today that it has been awarded a ... Defense Threat Reduction Agency (DTRA), a branch of the ... were selected after an intense competition among many of ... , Nanobiosym, and its commercial partner Nanobiosym Diagnostics, ...
... September 26, 2007Analyses conducted by researchers from Universit Lavals ... lake is affected by climate change. In an article ... Geophysical Research Letters, the international research team led by ... that aquatic life in Ward Hunt Lake, a body ...
... said today that the discovery of 11 new animal and ... the importance of conservation efforts in the ancient tropical forests ... tropical forests of a region known as Vietnams Green Corridor, ... well as three other plants new to science and exclusive ...
Cached Biology News:
... ZMD.437. Immunogen: Synthetic peptide derived from ... and rat ZO-1. Specificity: Specific for ... protein. Reactivity: Human Dog Rat Mouse ... cells frozen mouse liver heart blood vessel ...
Human/Mouse APLP-1 MAb (Clone 354020) ENTREZ GeneID: 333...
... glycoprotein ligand-1 (PSGL-1) mediate the earliest rolling ... endothelial cells at sites of inflammation. ... in mediating the interaction between neutrophils and ... recognition of PSGL-1 by either P-selectin or ...
Biology Products: